With more than a century of combined experience spanning the gamut from pancreas/GI tract issues in hepato-gastroenterology and infectious disease to the development of novel non-systemic (localized) therapeutic biologics and proteomics (protein engineering), the AzurRx BioPharma, Inc. (NASDAQ: AZRX) core science team is the real strength behind the company’s developing portfolio of recombinant therapies. AzurRx has come quite a long way on the strength of its science-driven approach and today stands tall upon the IP foundation of its two main pipeline programs. The lead candidate of which, MS1819 lipase, is currently in ongoing, open-label Phase IIa trials in EPI (exocrine pancreatic insufficiency) associated with chronic pancreatitis (CP). Human trialing where this novel, orally delivered, non-systemic (non-absorbable, locally-acting, does not reach systemic circulation), yeast-derived recombinant enzyme has already shown solid dose responses at various levels with no apparent safety issues.
Given such positive Phase IIa in vivo study data (reported in mid-April 2017), where the efficacy of MS1819 is characterized by a 20 percent increase in the coefficient of fat absorption in all patients (or CFA, the primary efficacy endpoint), AZRX is confident that its lead candidate will continue to show a…
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer